previous arrow
next arrow
Slider

Clinical

Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.

Read More

Research

Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.

Read More

Become a Partner

Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.

Learn More

Luminex Blog

Luminex Licensed Technologies Partner Spotlight: EpiCypher

EpiCypher delivers high-quality reagents for epigenetics and chromatin research

As one of Luminex’s Licensed Technologies Partners, EpiCypher is one of many companies that uses xMAP® Technology to deliver important solutions for improving research and molecular diagnostics. Based out of the Research Triangle Park in North Carolina, EpiCypher is a biotechnology company that helps scientists push the boundaries of research in chromatin regulation, chromatin mapping, and epigenetics.

Continue Reading >

Workflow of an LDT on the ARIES® System

 
Video Thumbnail
Workflow of an LDT on the ARIES® System
Clinical Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed. Read More Research Our xMAP® Technology and its flexible, open-architecture design is

The ARIES® System from Luminex offers you the flexibility to run IVD assays, as well as design and run lab developed tests. Using SYNCT™ software, you can easily create and run your own assays with the most common PCR technologies, including TAQMAN® and MultiCode®.

Watch more videos >

Luminex on Twitter


The @US_FDA has approved the drug Veklury (Remdesivir) for the treatment of COVID-19 requiring hospitalization. It is the first treatment to receive FDA approval. Read more here: https://t.co/xhVd57GsGS https://t.co/M0OBR9L0h0
h J R
@IDSE_Online: Using a rapid molecular diagnostic assay to identify VRE cut in-hospital mortality rates by nearly 80%. https://t.co/VbnGm4zeyl @UTexasPharmacy @Luminex #rapiddiagnostics #IDWeek2020
h J R
In this new @FrontImmunol study, multiplex immunoassays offer advantages for measuring cytokines in human plasma, which can be useful in diagnosing, tracking, & treating health disorders. Read the study here: https://t.co/CQmQPYALSL https://t.co/fF7RTw6Xen
h J R